XBiotech to begin constructing new R&D facility on 48-acre campus

XBiotech announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new four-story building, to be located close to the existing 46,000 ft manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company’s Natrunix rheumatology program. The new 46,000+ft facility will house clinical and medical operations, commercialization teams, and even incorporate wet laboratories, especially to enable ongoing infectious disease programs. John Simard, President and CEO of XBiotech commented, “We are excited to begin construction of what will be a unique and remarkable R&D facility. It will add significant operational capability to our existing manufacturing and R&D operations on the campus, and will create among the most capable biotechnology operations in Texas.”